




Instance: composition-en-ef95b389907181c6a50441289b7e7a0a
InstanceOf: CompositionUvEpi
Title: "Composition for rotateq Package Leaflet"
Description:  "Composition for rotateq Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp46ac42c3177ca9212e9ddaebe7281b79)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - rotateq"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What RotaTeq is and what it is used for</li>
<li>What you need to know before your child receives RotaTeq</li>
<li>How to use RotaTeq </li>
<li>Possible side effects</li>
<li>How to store RotaTeq</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What rotateq is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What rotateq is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>RotaTeq is an oral vaccine that helps protect infants and young children against gastroenteritis
(diarrhoea and vomiting) caused by rotavirus infection and may be given to infants from the age of
6 weeks to 32 weeks (see section 3). The vaccine contains five types of live rotavirus strains. When an
infant is given the vaccine, the immune system (the body s natural defences) will make antibodies
against the most commonly occurring types of rotavirus. These antibodies help protect against
gastroenteritis caused by these types of rotavirus.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take rotateq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take rotateq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use RotaTeq if
- your child is allergic to any of the components of this vaccine (see section 6 Contents of the
pack and other information).
- your child developed an allergic reaction after receiving a dose of RotaTeq or other rotavirus
vaccine.
- your child has previously had intussusception (a bowel obstruction in which one segment of
bowel becomes enfolded within another segment).
- your child was born with a malformation of the gastrointestinal system that might predispose for
intussusception.
- your child has any disease which reduces his/her resistance to infection.
- your child has a severe infection with a high temperature. It might be necessary to postpone the
vaccination until recovery. A minor infection such as a cold should not be a problem, but talk to
your doctor first.
- your child has diarrhoea or is vomiting. It might be necessary to postpone the vaccination until
recovery.
Warnings and precautions
Talk to your doctor or pharmacist before using RotaTeq if your child:</p>
<ul>
<li>has received a blood transfusion or immunoglobulins within the last 6 weeks.</li>
<li>has a close contact such as a household member who has a weakened immune system, e.g., a
person with cancer or who is taking medicines that may weaken the immune system.</li>
<li>has any disorder of the gastrointestinal system.</li>
<li>has not been gaining weight and growing as expected.</li>
<li>or the mother has taken any medicine during pregnancy that weakens the immune system.
After your child has received RotaTeq, contact a doctor/health care professional right away if your
child experiences severe stomach pain, persistent vomiting, blood in stools, a swollen belly and/or
high fever (see also section 4  Possible side effects ).
As always, please take care to wash your hands thoroughly after changing soiled nappies.<br />
As with other vaccines, RotaTeq may not completely protect all children who are vaccinated even
after all three doses have been given.<br />
If your child has already been infected with rotavirus but is not yet ill when vaccinated, RotaTeq may
not be able to prevent the illness. 
RotaTeq does not protect against diarrhoea and vomiting due to causes other than rotavirus. 
Other medicines and RotaTeq
RotaTeq may be given at the same time as your child receives other normally recommended
vaccinations, such as diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b,
inactivated or oral poliomyelitis, hepatitis B, pneumococcal conjugate and meningococcus group C
conjugate vaccines.
Tell your doctor or pharmacist if your child is taking, has recently taken or might take any other
medicines (or other vaccines).
RotaTeq with food and drink
There are no restrictions on taking food or liquid, including breast milk, either before or after
vaccination with RotaTeq. 
RotaTeq contains sucrose
If you have been told that your child has an intolerance to some sugars, inform your doctor/health care
professional before the vaccine is administered.<br />
RotaTeq contains sodium
This vaccine contains 37.6 mg sodium (main component of cooking/table salt) in each dose. This is
equivalent to 1.88% of the recommended maximum daily dietary intake of sodium for an adult.</li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take rotateq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take rotateq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>RotaTeq IS FOR ORAL USE ONLY.
A doctor or nurse will administer the recommended doses of RotaTeq to your child. The vaccine will
be given by gently squeezing the tube and delivering the vaccine into your child s mouth. 
The vaccine can be given without regard to food, liquid, or breast milk. 
In case your child spits out or regurgitates most of the vaccine dose, a single replacement dose may be
given at the same vaccination visit. 
Under no circumstance should this vaccine be administered by injection. 
The first dose (2 ml) of RotaTeq may be given from the age of 6 weeks and should be given before
12 weeks of age (about 3 months). RotaTeq may be given to infants who were born early provided that
the pregnancy had lasted at least 25 weeks. These infants should receive the first dose of vaccine
between 6 and 12 weeks after birth.
Your child will receive 3 doses of RotaTeq given at least four weeks apart. It is important that your
child receives all 3 doses of the vaccine for protection against rotavirus. It is preferred that all three
doses should be given by the age of 20-22 weeks and at latest all three doses should be given by the
age of 32 weeks.
When RotaTeq is given to your child for the first dose, it is recommended that your child also receives
RotaTeq (and not another rotavirus vaccine) to complete the vaccination course. 
If you forget an appointment for RotaTeq
It is important that you follow the instructions of your doctor/health care professional regarding your
child s return visits for the follow-up doses. If you forget or are not able to go back to your
doctor/health care professional at the scheduled time, ask him or her for advice. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all vaccines and medicines, this vaccine can cause side effects, although not everybody gets
them.<br />
Contact a doctor/health care professional right away if your child experiences one of the following
symptoms:</p>
<p>Allergic reactions (frequency cannot be estimated from the available data), which may be severe
(anaphylaxis), and may include: allergic swelling that may affect the face, lips, tongue or throat.</p>
<p>Bronchospasm (rare, may affect up to 1 in 1000 infants). This may present as wheezing,
coughing or difficulty breathing.</p>
<p>Severe stomach pain, persistent vomiting, blood in stools, a swollen belly and/or high fever.
These could be symptoms of a very rare (may affect up to 1 in 10,000 infants), but serious, side
effect called intussusception (a bowel obstruction in which one segment of bowel becomes
enfolded within another segment).
The following other side effects reported with the use of RotaTeq were:
  Very common (may affect more than 1 in 10 infants): fever, diarrhoea, vomiting
  Common (may affect up to 1 in 10 infants): infections of the upper respiratory system
  Uncommon (may affect up to 1 in 100 infants): stomach pains (see also above for signs of a
very rare side effect of intussusception), runny nose and sore throat, ear infection, rash, blood
in stool
  Rare (may affect up to 1 in 1000 infants): hives
  Not known (frequency cannot be estimated from the available data): irritability
In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between
breaths may occur for 2-3 days after vaccination.
Ask your doctor/health care professional if you want more information about side effects for RotaTeq.<br />
Reporting of side effects
If your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly via the national reporting
system listed in Appendix V. By reporting side effects you can help provide more information on the
safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store rotateq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store rotateq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date
refers to the last day of that month.
Store and transport refrigerated (2  C to 8  C). Keep the dosing tube in the outer carton in order to
protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help to protect the environment.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What RotaTeq contains
The active substances in RotaTeq are 5 human-bovine reassortant rotavirus strains:
G1 
2.2 x 106 Infectious Units
G2 
2.8 x 106 Infectious Units
G3 
2.2 x 106 Infectious Units
G4 
2.0 x 106 Infectious Units
P1A[8] 
2.3 x 106 Infectious Units
The other ingredients in RotaTeq are: sucrose, sodium citrate, sodium dihydrogen phosphate
monohydrate, sodium hydroxide, polysorbate 80, culture media (containing inorganic salts, amino
acids and vitamins), and purified water.<br />
What RotaTeq looks like and contents of the pack
Oral solution
This vaccine is contained in a single-dose tube and is a pale yellow clear liquid that may have a pink
tint.
RotaTeq is available in pack size of 1, 10 dosing tubes. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder: Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN Haarlem,
The Netherlands.
Manufacturer Responsible for Batch Release: Merck Sharp and Dohme, B.V., Waarderweg, 39, 2BN, Haarlem, The Netherlands
For any information about this medicinal product, please contact the local representative of the
Marketing Authorisation Holder.
Belgi /Belgique/Belgien
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370.5.2780.msd_lietuva@merck.com</p>
<pre><code>       ,
</code></pre>
<p>.: + 359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o. 
Tel.: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft.
Tel.: + 36.1.888.5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited.
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com 
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48.22.549.51.msdpolska@merck.com
France
MSD France
T l: +33 (0)1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: +385 1 66 11 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L
Tel: + 4021 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386.1.520.4msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r.* Tel: +421 2 58282dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi </p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 :  800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371.67364.msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in: 
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website:
http://www.ema.europa.eu.</p>
<hr />
<p>The following information is intended for health care professionals only:
Instructions
To administer the vaccine:
Tear open the protective bag and remove the dosing tube.
Clear the fluid from the dispensing tip by holding tube vertically and
tapping the twist-off cap.
Open the dosing tube in 2 easy motions:
1. Puncture the dispensing tip by screwing cap clockwise until it
becomes tight.
2. Remove cap by turning it counterclockwise.<br />
Administer dose by gently squeezing liquid into infant's mouth toward
the inner cheek until dosing tube is empty. (A residual drop may remain
in the tip of the tube.)  </p>
<p>Discard the empty tube and cap in approved biological waste containers
according to local regulations.
Any unused product or waste material should be disposed of in accordance with local requirements.
See also section 3. How to use RotaTeq.</p>         </div>"""      



Instance: composition-da-ef95b389907181c6a50441289b7e7a0a
InstanceOf: CompositionUvEpi
Title: "Composition for rotateq Package Leaflet"
Description:  "Composition for rotateq Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp46ac42c3177ca9212e9ddaebe7281b79)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - rotateq"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før dit barn vaccineres med RotaTeq
3. Sådan får dit barn RotaTeq
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What rotateq is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What rotateq is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>RotaTeq er en oral vaccine (gives gennem munden), der hjælper med at beskytte spædbørn og små
børn mod gastroenteritis (diarré og opkastning), der skyldes rotavirus-infektion. RotaTeq kan
anvendes til spædbørn i alderen 6 uger til 32 uger (se punkt 3). Vaccinen indeholder 5 levende
rotavirus-stammer. Når et spædbarn får vaccinen, vil immunsystemet (kroppens naturlige
forsvarssystem) producere antistoffer imod de hyppigst forekommende typer af rotavirus. Disse
antistoffer hjælper med at beskytte imod gastroenteritis, der skyldes disse typer af rotavirus.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take rotateq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take rotateq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke RotaTeq
− 
hvis dit barn er allergisk over for et eller flere af vaccinens hjælpestoffer (se punkt 6. Pakningsstørrelser og yderligere oplysninger).
− 
hvis dit barn udviklede en allergisk reaktion efter at have fået en dosis RotaTeq eller anden
rotavirus-vaccine.
− 
hvis dit barn tidligere har haft invagination (tarmobstruktion i hvilken et tarmafsnit forskyder
sig ind i et andet).
− 
hvis dit barn er født med misdannelser i mavetarmkanalen, som kan disponere for invagination.
− 
hvis dit barn har en sygdom, som reducerer dets modstandskraft imod infektioner.
− 
hvis dit barn lider af en alvorlig infektion med høj feber. Det kan være nødvendigt at udskyde
vaccinationen, indtil barnet er raskt. En mindre infektion såsom en forkølelse burde ikke være
noget problem, men tal først med lægen.
− 
hvis dit barn har diarré eller kaster op. Det kan være nødvendigt at udsætte vaccinationen, indtil
barnet er raskt.
Advarsler og forsigtighedsregler
Kontakt lægen eller apotekspersonalet, hvis dit barn:
− 
har fået blodtransfusion eller immunglobuliner inden for de seneste 6 uger.
− 
har en tæt kontakt, f.eks. med et medlem af husstanden, der har svækket immunsystem, f.eks. en
person med cancer, eller en person, der tager lægemidler, der kan svække immunsystemet.<br />
24
− 
har en sygdom i mavetarmkanalen. 
− 
ikke har taget på og ikke er vokset som forventet.
− 
eller moderen under graviditeten har taget lægemidler, der svækker immunsystemet.
Kontakt straks en læge/sundhedsplejerske hvis dit barn, efter at have fået RotaTeq, får svære
mavesmerter, vedvarende opkastning, blod i afføringen, opsvulmet mave og/eller høj feber (se også
punkt 4 "Bivirkninger").
Som altid skal man være omhyggelig med at vaske hænderne grundigt efter at have skiftet brugte
bleer.
Som alle andre vacciner beskytter RotaTeq måske ikke alle vaccinerede børn fuldstændigt, selv ikke
efter at alle tre doser er blevet givet.
Hvis dit barn allerede er smittet med rotavirus, men endnu ikke er sygt, når det vaccineres, vil RotaTeq
måske ikke være i stand til at forhindre sygdommen.<br />
RotaTeq beskytter ikke imod diarré og opkastning på grund af andre årsager end rotavirus.<br />
Brug af anden medicin sammen med RotaTeq
RotaTeq kan gives samtidig med, at dit barn får andre normalt anbefalede vaccinationer såsom
vacciner imod difteri, stivkrampe, kighoste, Haemophilus influenzae type b, inaktiveret eller oral (som
gives gennem munden) poliomyelitis-, hepatitis B- og konjugerede pneumokokvacciner og
konjugerede gruppe C-meningokokvacciner. 
Fortæl altid lægen eller apotekspersonalet, hvis dit barn bruger anden medicin (eller andre vacciner),
for nylig har brugt anden medicin (eller andre vacciner) eller planlægger at bruge anden medicin (eller
andre vacciner).
Brug af RotaTeq sammen med mad og drikke
Der er ingen begrænsninger for indtagelse af mad eller væske, herunder modermælk, før eller efter
vaccination med RotaTeq. 
RotaTeq indeholder saccharose</p>
<p>Hvis du har fået at vide, at dit barn har en intolerans over for visse typer sukker, skal du underrette din
læge/sundhedsplejerske, før vaccinen indgives.<br />
RotaTeq indeholder natrium
Denne vaccine indeholder 37,6 mg natrium (hovedbestanddelen i køkkensalt/bordsalt) i hver dosis.
Dette svarer til 1,88 % af den anbefalede maksimale daglige indtagelse af natrium for en voksen.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take rotateq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take rotateq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>RotaTeq ER KUN TIL ORAL INDTAGELSE.
En læge eller sygeplejerske vil give de anbefalede doser af RotaTeq til dit barn. Vaccinen vil blive
givet ved at trykke forsigtigt på tuben og indgive vaccinen i barnets mund. Vaccinen kan gives uden
hensyntagen til indtagelse af føde, væske eller modermælk.
I tilfælde af at barnet spytter vaccinen ud eller gylper det meste af vaccinedosen op, kan der gives en
enkelt erstatningsdosis i løbet af den samme konsultation.
Denne vaccine må under ingen omstændigheder indgives ved injektion.
25
Den første dosis (2 ml) af RotaTeq kan gives fra 6-ugers-alderen, og bør gives før 12-ugers-alderen
(omkring 3 måneder). RotaTeq kan gives til for tidligt fødte spædbørn under forudsætning af, at
graviditeten har varet mindst 25 uger. Disse spædbørn skal have den første dosis af vaccinen mellem 6
og 12 uger efter fødslen.
Dit barn skal have 3 doser RotaTeq, med mindst fire ugers mellemrum. Det er vigtigt, at dit barn får
alle 3 doser af vaccinen for at opnå maksimal beskyttelse imod rotavirus. Det er at foretrække, at alle
tre doser gives før 20-22-ugers-alderen, og alle tre doser skal senest være givet ved 32-ugers-alderen.
Når dit barn får RotaTeq som den første dosis, anbefales det, at dit barn også får RotaTeq (og ikke en
anden rotavirus-vaccine) for at fuldføre vaccinationsrunden.
Hvis du har glemt en konsultation
Det er vigtigt, at du følger din læges/sundhedsplejerskes instruktioner vedrørende dit barns
konsultationer for opfølgende doser. Hvis du glemmer eller ikke er i stand til at møde hos din
læge/sundhedsplejerske på det aftalte tidspunkt, så spørg ham eller hende til råds. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Denne vaccine kan som alle andre vacciner og alle andre lægemidler give bivirkninger, men ikke alle
får bivirkninger.
Kontakt straks en læge/sundhedsplejerske, hvis dit barn får et af følgende symptomer:</p>
<ul>
<li>
<p>Allergiske reaktioner (hyppigheden kan ikke vurderes ud fra forhåndenværende data), som
kan være alvorlige (anafylaksi), og som kan omfatte: allergisk hævelse som kan påvirke
ansigt, læber, tunge eller svælg.</p>
</li>
<li>
<p>Bronkospasmer (sjælden, kan forekomme hos op til 1 ud af 1.000 spædbørn). Dette kan vise
sig som hvæsende vejrtrækning, hoste eller vejrtrækningsbesvær.</p>
</li>
<li>
<p>Svære mavesmerter, vedvarende opkastning, blod i afføringen, opsvulmet mave og/eller høj
feber. Disse kan være symptomer på en meget sjælden (kan forekomme hos op til 1 ud af
10.000 spædbørn) men alvorlig bivirkning kaldet invagination (tarmobstruktion hvor et stykke
af tarmen bliver foldet ind i et andet tarmstykke).
Følgende andre bivirkninger er rapporteret ved anvendelse af RotaTeq:</p>
</li>
<li>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 spædbørn): feber, diarré,
opkastning.</p>
</li>
<li>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 spædbørn): infektioner i de øvre luftveje.</p>
</li>
<li>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 spædbørn): mavesmerter (se også
ovenfor vedrørende tegn på den meget sjældne bivirkning invagination), løbende næse og ondt
i halsen, øreinfektion, udslæt, blod i afføringen.</p>
</li>
<li>
<p>Sjælden (kan forekomme hos 1 ud af 1.000 spædbørn): nældefeber.</p>
</li>
<li>
<p>Ikke kendt (hyppigheden kan ikke vurderes ud fra forhåndenværende data): irritabilitet.
Hos børn, der er født meget for tidligt (i løbet af eller før 28. svangerskabsuge) kan der opstå længere
pauser i vejrtrækningen end normalt, dette kan ske i 2-3 dage efter vaccination.
26
Spørg din læge/sundhedsplejerske, hvis du ønsker flere oplysninger om bivirkningerne ved RotaTeq.
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information
om sikkerheden af dette lægemiddel.</p>
</li>
</ul>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store rotateq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store rotateq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar denne vaccine utilgængeligt for børn.
Brug ikke denne vaccine efter den udløbsdato, der står på etiketten efter EXP. Udløbsdatoen er den
sidste dag i den nævnte måned. 
Opbevares i køleskab og transporteres nedkølet (2 °C - 8 °C). Doseringstuben skal opbevares i den
ydre pakning for at beskytte mod lys.
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>RotaTeq indeholder:
Aktive stoffer i RotaTeq er 5 human-bovine reassortante rotavirus-stammer.
G1 
2,2 x 106 Infektiøse enheder
G2 
2,8 x 106 Infektiøse enheder
G3 
2,2 x 106 Infektiøse enheder
G4 
2,0 x 106 Infektiøse enheder
P1A[8] 
2,3 x 106 Infektiøse enheder
De øvrige indholdsstoffer i RotaTeq er: saccharose, natriumcitrat,
natriumdihydrogenphosphatmonohydrat, natriumhydroxid, polysorbat 80, dyrkningsmedier
(indeholdende uorganiske salte, aminosyrer og vitaminer) og renset vand.
Udseende og pakningsstørrelser
Oral opløsning.
Denne vaccine leveres i en enkeltdosistube og er en lysegul, klar væske, der kan have et lyserødt skær.
RotaTeq fås i pakningsstørrelser på 1 eller 10 stk. doseringstuber. Ikke alle pakningsstørrelser er
nødvendigvis markedsført.
Indehaveren af markedsføringstilladelsen og fremstiller
Indehaver af markedsføringstilladelsen: Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN
Haarlem, Holland
Fremstiller med ansvar for batchfrigivelse: Merck Sharp and Dohme, B.V., Waarderweg, 39, 2031
BN, Haarlem, Holland
Hvis du vil have yderligere oplysninger om RotaTeq, skal du henvende dig til den lokale repræsentant:
27
België/Belgique/Belgien
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@msd.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370.5.2780.247
msd_lietuva@merck.com
България
Мерк Шарп и Доум България ЕООД, 
тел.: + 359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@msd.com
Česká republika
Merck Sharp &amp; Dohme s.r.o. 
Tel.: +420 233 010 111
dpoc_czechslovak@merck.com
Magyarország
MSD Pharma Hungary Kft.
Tel.: + 36.1.888.5300
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4000
dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited.
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de 
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com 
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Ελλάδα
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48.22.549.51.00
msdpolska@merck.com
France
MSD France
Tél: +33 (0)1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: +385 1 66 11 333
croatia_info@merck.com
România
Merck Sharp &amp; Dohme Romania S.R.L
Tel: + 4021 529 29 00
msdromania@merck.com
28
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@msd.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386.1.520.4201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s. r.* Tel: +421 2 58282010
dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi 
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ:  800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371.67364.224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret 
Andre informationskilder
Du kan finde yderligere oplysninger om RotaTeq på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu. 
29</p>
<hr />
<p>Nedenstående oplysninger er til læger og sundhedspersonale:
Anvisninger
Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer.
Se også punkt </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-ef95b389907181c6a50441289b7e7a0a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for rotateq Package Leaflet for language en"
Description: "ePI document Bundle for rotateq Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-ef95b389907181c6a50441289b7e7a0a"
* entry[0].resource = composition-en-ef95b389907181c6a50441289b7e7a0a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpef95b389907181c6a50441289b7e7a0a"
* entry[=].resource = mpef95b389907181c6a50441289b7e7a0a
                            
                    
Instance: bundlepackageleaflet-da-ef95b389907181c6a50441289b7e7a0a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for rotateq Package Leaflet for language da"
Description: "ePI document Bundle for rotateq Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-ef95b389907181c6a50441289b7e7a0a"
* entry[0].resource = composition-da-ef95b389907181c6a50441289b7e7a0a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpef95b389907181c6a50441289b7e7a0a"
* entry[=].resource = mpef95b389907181c6a50441289b7e7a0a
                            
                    



Instance: mpef95b389907181c6a50441289b7e7a0a
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product RotaTeq oral solution"
Description: "RotaTeq oral solution"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/06/348/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "RotaTeq oral solution"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: ef95b389907181c6a50441289b7e7a0aListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "rotateq"

* status = #current
* mode = #working

* title = "List of all ePIs associated with rotateq"

* subject = Reference(mp46ac42c3177ca9212e9ddaebe7281b79)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#rotateq "rotateq"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-ef95b389907181c6a50441289b7e7a0a) // rotateq en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-ef95b389907181c6a50441289b7e7a0a) // rotateq da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-ef95b389907181c6a50441289b7e7a0a
InstanceOf: List

* insert ef95b389907181c6a50441289b7e7a0aListRuleset
    